just an fyi, VICL lost about 2/3 value on the failure, as did AEZS lost about 2/3 on their Perifosine trial failure 1/ 1/2 yrs ago. AEZS continues falling and is now about 1/10 the value that it was before their failure. The two companies look very similar imo, and VICL mkt cap is still much higher than AEZS. Also VICL may suffer dilution around end of year. IMO, I would jump on a safer alternative like AMRN or NVIV. GLTA, all imo, do your own dd.
So you loaded up right before the hammer fell? why buy more now - either sell and take the loss or wait until this finally settles (which it hasn't quite yet). And why is this a buy - what is your investment thesis with regard to the remaining clinical assets?